Podcasts about treatments

Stories from a Giant and Gadfly Discover the Protest Music of RainFall!-- like "The Antidepressant Blues!" Today, we are delighted to spend some time with a dear friend and highly esteemed colleague, Dr. David Antonuccio. David is a retired Clinical Psychologist and Professor Emeritus in the Dept. of Psychiatry and Behavioral Sciences at the University of Nevada, Reno, School of Medicine. In addition to his academic work, David had his own clinical practice for 40 years. He has published over 100 academic articles and multiple books, primarily on the treatment of depression, anxiety, or smoking cessation. Since his retirement from practice in 2020, he has been making music as part of a duo called RainFall, with his musical partner Michael Pierce. Their music can be found on Spotify, Apple music, and Soundcloud, among other streaming services. I first became familiar with David when a colleague recommended his article entitled: "Psychotherapy versus medication for depression: challenging the conventional wisdom with data," which was published in Professional Psychology: Research and Practice way back in 1995. The article blew my socks off. In the first place, he had come to the many of the same conclusions I had come to, that antidepressants had few "real" effects above and beyond their placebo effects. However, he also had incredible insights into some of the problems and loopholes with drug company research studies on antidepressants, so I tried to get as many colleagues and students as possible to read that article. Here is the article link Although I had never met David, he became my hero. One day, while I was giving one of my two-day CBT workshops in Nevada, I was singing his praises and urging participants to read that classic article, but, unexpectedly, some people started chuckling. At a break, I asked someone why people had been laughing. They said, "Didn't you know that David Antonuccio is here attending this workshop? He was out visiting the bathroom when you were singing his praises, so he didn't hear you!" And that's how we met! I couldn't believe my good fortune in meeting this brilliant and humble man in person. And to my good fortune, we became good friends right off the bat and eventually did a lot of fun professional work together, like our exciting conference challenging the chemical imbalance theory of depression which we called the Rumble in Reno. I was also proud to be included as a co-author in a popular article with David and William Danton reviewing the brilliant work of Irving Kirsch. Kirsch had re-analyzed all the data on antidepressants in the FDA archives and concluded that the chemicals called "antidepressants" had few, if any, clinically significant effects above and beyond their placebo effects. In that paper, we also emphasized the ongoing power struggle between the needs of science and the needs of marketing. Science is devoted to discovering and reporting the truth, based on research, regardless of where it leads, while marketing, sadly, is ultimately loyal to the bottom line, even if deception is required. Here is the link to our article: And here is the full reference: Antonuccio, D. O., Burns, D., & Danton, W. G. (2002). Antidepressants: A Triumph of Marketing over Science? Prevention and Treatment, 5, Article 25. Web link: http://journals.apa.org/prevention/volume5/toc-jul15-02.htm I was sad when David retired from his clinical, teaching, and research career a number of years ago in order to spend more time on creating and recording music because, a passion he'd put on the shelf during the most active years of his career. I felt we'd lost an important and courageous leader in the behavioral sciences, and felt an emptiness, like an important pioneer was suddenly missing. The following link provides a highly readable brief overview of David's career focus and interests. I was thrilled to learn just recently that David has partly resumed his role as gadfly of the behavioral sciences, rejoining the fight for science, ethics and for truth, regardless of where that leads or whose feathers are ruffled. And now, we sit down together to reminisce about his personal life and experiences with many of the greats in our field, like Dr. David Healey, Irving Kirsch, and others who have also stood up for the truth, based on their research, in spite of intense opposition from the establishment. And, today David also brings us his music, with his colleague, Michael Pierce, RainFall. Some of his music has psychiatric / psychological themes, like his "Antidepressant Blues," Some of David's music has humanistic and political themes. He said: Here's a song we just released yesterday that i will assume would not be relevant to the podcast. It is called Final Embrace and was inspired by a heart-breaking international wire photo of a Salvadoran immigrant father hugging his daughter, both deceased, in the rio grande in 2019. Here's the link to the original news story. David's two-man group, RainFall, wrote and recorded the original acoustic version of this song in 2020. He explains: We decided to record a more dynamic updated version of the song with some electric guitar chords, electric bass, and drums. We are calling it "Final Embrace Electric". The story is still heart-breaking, and it still makes me cry to sing it. Here is a link to the new version of the song, And here are the heart-breaking lyrics: Final Embrace Electric (For Oscar and Valeria) By RainFall (David Antonuccio and Michael Pierce) I'm sorry I couldn't help you I'm sorry you lost your life You took a deadly risk I'm sorry for your wife What were you supposed to do? Stay home and watch your family die? Or take a chance at freedom Reach for the sky Some say you should have known better They say that you are a criminal But they don't know your fear, your pain, your hunger For them it's the principle Some say we were here first It's not our problem Despite your dire thirst We're full, no more asylum Let's ask them what they would do If their family were faced with danger If they're honest, they'd take the chance Hope for kindness from a stranger You tried to get in the front door But it was slammed closed So you swam the deadly current Despite the perilous flow You never lost your grip Though the river was not crossable Only another parent can know How that is even possible Everyone can tell you loved your daughter Even in that place You never let her go It was your final embrace I'm sorry I couldn't help you I'm sorry you lost your life You took a deadly risk I'm so sorry for your wife Everyone can tell you loved your daughter Even in that place You never let her go It was your final embrace Your final embrace It was your final embrace It was your final embrace   Thank you for joining us today. Stayed tuned for Part 2 of the David Antonuccio interview next week! David, Rhonda, and David

Lyme and vector disease treatments are highly effective when you incorporate these essential steps. In this episode, I've compiled conversations with vector disease experts on the best supplements, therapies and protocols. You may be missing a step that could improve your healing. Learn more, listen now.   ✅ Start healing with us! Learn more about our virtual clinic:  https://drruscio.com/virtual-clinic/ The Horowitz Multiple Systemic Infectious Disease Syndrome Questionnaire: https://mailchi.mp/8e5ccb1a9297/lyme-questionnaire  

In this powerful episode, Duane sits down with filmmaker Benjamin Flaherty to discuss his hard-hitting documentary, Shuffle. The film pulls back the curtain on the "Florida Shuffle"—a predatory cycle in the billion-dollar addiction treatment industry where vulnerable individuals are "brokered" between facilities for insurance payouts.Benjamin shares his own journey of recovery and explains how his personal experience allowed him to gain unprecedented access to a community often silenced or exploited. This conversation explores the dark intersection of greed and healthcare, the resilience of the human spirit, and why the current treatment system desperately needs transparency.Key Discussion PointsBenjamin's Recovery Journey: How a moment of clarity at age 41 led Benjamin from "professional alcoholism" to a transformative experience in treatment.The Origins of Shuffle: A chance conversation in an AA meeting revealed a disturbing trend: recovery call centers becoming a primary source of employment for those in early sobriety.What is the "Florida Shuffle"? Benjamin explains how the Affordable Care Act (ACA) unintentionally created a loophole where "patient brokers" poach insured individuals, profiting from their relapses.The Statistic that Shocks: There are currently more private substance abuse treatment centers in the U.S. than there are McDonald's restaurants.Witnessing the Cycle: The emotional weight of filming Corey and Nicole—two individuals caught in the cycle of being "bought and sold" by treatment facilities.The "Driveway Recordings": Why Benjamin chose to use raw, iPhone voice memos for the film's narration to maintain emotional authenticity.Maintaining Hope: Despite the systemic corruption, the film highlights the incredible resilience of those in recovery and the fact that healing is still possible.Notable Quotes"Stopping a substance is the entry card for admission. That's not the whole thing. There's a lot of work to do, and none of us know that until we find it out in our own way." — Benjamin Flaherty"We've now made relapse profitable. We've incentivized the struggle by providing substandard care because an insurance card is like a blank check." — Benjamin Flaherty"I approached my time with Corey not as a filmmaker first, but as a person in recovery. I had to witness it to make it impossible to ignore." — Benjamin FlahertyResources MentionedThe Documentary: Shuffle (also referred to as Stop the Shuffle)Website: stoptheshuffle.com — Find theater locations, tickets, and upcoming streaming info.Social Media: Follow the movement on Instagram @StopTheShuffle.Episode CreditsIf you like this podcast and are thinking of creating your own, consider talking to my producer, Emerald City Productions. They helped me grow and produce the podcast you are listening to right now. Find out more at https://emeraldcitypro.com Let them know we sent you.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A vegan diet nearly cost him his life, leading to severe anorexia and chronic Lyme disease. On episode 855 of the Savage Perspective Podcast, host Robert Sikes sits down with Frank Bohne to hear his unbelievable story. Frank shares the truth about his 10 weeks of forced treatment for his eating disorder, how his testosterone plummeted, and his eventual recovery through a raw carnivore diet. This conversation covers his health journey, from malnourishment to butchering and eating his own raw meat.Ready to build a strong and healthy body with a proven method? Join Robert's FREE Bodybuilding Masterclass to learn the exact steps for optimizing your health and physique. Sign up here: https://www.ketobodybuilding.com/registration-2Follow Frank on IG: https://www.instagram.com/instafrank95/Get Keto Brick: https://www.ketobrick.com/Subscribe to the podcast: https://open.spotify.com/show/42cjJssghqD01bdWBxRYEg?si=1XYKmPXmR4eKw2O9gGCEuQChapters:0:00 - How a Vegan Diet Led to Anorexia & Lyme Disease 0:38 - Guest Intro: Frank Bohne's Radical Transformation 2:55 - What Convinced Him to Go Vegan? 4:09 - His Shocking Weight at 6'1" on a Vegan Diet 6:15 - Was He Binging and Purging or Just Malnourished? 6:41 - The Moment He Realized His Health Was Collapsing 8:13 - Inside the "Psychological Warfare" of Anorexia Treatment 9:56 - His Testosterone Levels Were in the Double Digits 12:00 - The Controversial "Everything in Moderation" Treatment Method 15:09 - What Was His Family Life Like During His Decline? 16:29 - How Do They Measure "Progress" in Treatment? 18:15 - Did He Quit Veganism After Leaving the Hospital? 21:00 - What Kind of "Food" Do They Serve in Treatment? 22:39 - From Veganism to a Keto-Carnivore Diet 24:41 - How Did He Get Chronic Lyme Disease? 26:32 - The Joe Rogan Episode That Changed His Life 28:34 - A Word From Our Host: No Ads, Just Value 30:16 - Why He Started Eating Raw Sheep Eyes 32:48 - Does He Eat Primarily Sheep or Beef? 34:36 - Why Lamb is One of the Best Keto-Carnivore Foods 37:00 - How Long Does One Sheep Last Him? 38:25 - How He Stores a Whole Lamb in His Toyota Prius 39:18 - Does He Prefer a Certain Taste or Texture? 42:55 - Is This Lifestyle Another Form of Eating Disorder? 45:32 - How the Vegan Community Reacts to Him Now 48:20 - His Plan to Create More Butchering Content 49:23 - How Much Does It Cost to Buy and Butcher a Whole Sheep? 52:40 - What's the Future Hold for Frank? 55:57 - How Does He Vet Farmers to Avoid Parasites in Raw Meat? 58:09 - Where to Find More From Frank Bohne

In this key episode of Parallax, Dr Ankur Kalra sits down with Prof Naveed Sattar to explore how recent therapeutic breakthroughs are fundamentally reshaping the cardiologist's approach to diabetes management. Through real-world case discussions, Dr Sattar demonstrates practical decision-making for patients across the spectrum - from pre-diabetes to established CAD with Type 2 diabetes. He addresses the tension between robust evidence and cost barriers that limit widespread implementation, while acknowledging unprecedented patient demand driven by genuine quality of life improvements. The conversation concludes with insights on obesogenic environments and the hope that increased competition will ultimately democratize access to these transformative therapies. Questions and comments can be sent to "podcast@radcliffe-group.com" and may be answered by Ankur in the next episode. Host: @AnkurKalraMD and produced by: @RadcliffeCardio Parallax is Ranked in the Top 100 Health Science Podcasts (#48) by Million Podcasts.

In this episode, Dr. Killeen breaks down the Peak–End Rule and why it plays such a big role in how patients remember treatment discussions and make decisions. He shares a simple shift in how you sequence options and frame pros and cons that can dramatically improve clarity, confidence, and case acceptance. Small tweaks in the order of your conversation can make a surprisingly big difference.

Am I the Genius? is the show where you get real answers to questions you've always wondered but didn't think to ask. Subscribe on YouTube - youtube.com/@amithegenius?sub_confirmation=1 Am I the Jerk? on Instagram - instagram.com/amithegenius Am I the Jerk? on Spotify - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://open.spotify.com/show/0uEkxvRMpxLuuHeyPVVioF?si=b279dadfe593432b⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ x.com/amithejerk facebook.com/amithejerk SUBMIT YOUR OWN STORIES HERE ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠http://amithejerk.com/submit⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Mint Mobile - Get this new customer offer and your 3-month Unlimited wireless plan for just 15 bucks a month at MINTMOBILE.com/AITJ Quince - Keep it classic and cool — with long-lasting staples from Quince. Go to Quince.com/AITJ for free shipping on your order and three hundred and sixty-five -day returns. EveryPlate - Dig into these flavor-packed meals your household will love. New customers can enjoy this special offer of only $1.99 a meal. Go to everyplate.com/podcast and use code AITG199 to get started. Green Chef - Head to Greenchef.com/50AITJ and use code 50AITJ to get fifty percent off your first month, then twenty percent off for two months with free shipping. Lola Blankets - Get 35% off your entire order at Lolablankets.com by using code AITJ at checkout. Uncommon Goods - To get 15% off your next gift, go to UncommonGoods.com/AITJ Don't miss out on this limited-time offer. Uncommon Goods. Learn more about your ad choices. Visit megaphone.fm/adchoices

(Repeat episode) - SEASON 11 Coming SoonMy website My Instagram

Between Salem's Lot and Poltergeist Tobe Hooper gave us a reason to fear the carnival.  You never know whats lurking under the attractions of the bizarre.  For our 166th podcast we give the Horror 101 Treatment to The Funhouse.  This movie is heavily steeped in 80s fun...Show Highlights:01:00 Prelude to Terror...03:30  A 50th Birthday Surprise...06:30  Tobe Hooper Films...12:10  The Psycho Halloween Beginning...14:20  Don't go near that Carnival...16:20  God is Watching You!17:50  The Barkers! (Kevin Conway)19:50  The Strippers...20:45  Let's Spend the Night...22:30  Funhouse Attractions...23:50  Witnessing Murder...27:25  Finders Keepers...31:30  Buzz's Misfortune...36:00  Liz Trapped...37:00  Carney Showdown...40:30  Crunch Job...44:30  Scoring the Film...51:15  Conclusion!  Thanks for Listening!

Text and Be HeardSports betting didn't just get bigger; it got faster, simpler, and stickier. We dig into how “responsible gambling” became the industry's soft sell while the real engine—microbetting, live props, and algorithmic nudges—pushes users toward rapid, compulsive loops. Our guest shares why he walked away from a sportsbook-backed media role and how the game changed once wagers moved from the window to the phone, from a weekend bet to constant yes or no clicks designed to escalate.We get real about who's most at risk: 18 to 24-year-olds with competitive fire, athletes who think their game IQ protects them, and families that unknowingly normalize “small” parlays. The warning is clear and actionable—delete the apps, avoid the group chats that make betting feel normal, and redirect that energy into training, study, and long-term investing that compounds rather than consumes. Along the way, we unpack the broader wellness bill: sleep erosion, worse food choices, hijacked attention, and a nervous system stuck on high alert. This isn't only a money problem; it's mental, emotional, and physiological.We also challenge false comfort from league policies and integrity talk. Trimming limits on a few markets won't fix a product built for speed and repetition. What moves the needle is early prevention, honest education in schools and gyms, and accessible support that isn't steered by industry partnerships. If states collect treatment dollars, people should be able to use them—yet access stays hard while advertising stays easy. We argue for a public health approach that puts player protection and prevention first and offers clear alternatives that build wealth and well-being over time.If this resonates, share it with someone who needs a straight answer about betting apps. Subscribe for more candid conversations on recovery, prevention, and performance—and leave a review to help others find the show.Support the showRecovery is Beautiful. Go Live Your Best Life!!Facebook Group - Recovery Freedom Circle | FacebookYour EQ is Your IQYouTube - Life Is Wonderful Hugo VRecovery Freedom CircleThe System That Understands Recovery, Builds Character and Helps People Have Better Relationships.A Life Changing Solution, Saves You Time, 18 weekswww.lifeiswonderful.love Instagram - Lifeiswonderful.LoveTikTok - Lifeiswonderful.LovePinterest - Lifeiswonderful.LoveX - LifeWonderLoveLinkedIn - Hugo Vrsalovic LinkedIn - The 1% in Recovery

Two families. Two different kinds of catastrophic failure. One expert to help us understand both. Psychotherapist Shavaun Scott — author of The Minds of Mass Killers — joins Hidden Killers for an extended examination of the psychology behind family annihilation and the systemic failures of America's addiction treatment industry.The Paul Caneiro trial continues in Monmouth County, New Jersey. Prosecutors allege Paul murdered his brother Keith, sister-in-law Jennifer, and their children Jesse and Sophia after Keith discovered Paul had stolen $78,000 from a trust account. The violence was staggering — Sophia was stabbed 17 times and allegedly still alive when the fire started. Shavaun explains what drives someone to kill everyone they love rather than face accountability, what overkill reveals about psychological state, and how experts distinguish genuine grief from performance.The Nick Reiner tragedy exposed the failures of addiction treatment. The Reiner family had resources most families can only dream of, and Rob and Michele Reiner are still dead. Shavaun examines the $42 billion industry where relapse is profitable, where insurance companies override clinical judgment, where outcome tracking doesn't exist. We identify who blocks reform and ask whether meaningful change is even possible. From the psychology of mass family killing to the financial incentives keeping broken systems in place — this is essential analysis of how institutions fail the people they're supposed to protect.#ShavaunScott #PaulCaneiro #NickReiner #RobReiner #KeithCaneiro #FamilyAnnihilation #AddictionCrisis #ColtsNeck #TreatmentFailure #HiddenKillersJoin Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspodInstagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/tonybpodListen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.

She survived an ambulance crash. Relearned how to walk. Relearned how to talk. Came back stronger than before.And then something the size of a pinhead almost ended it all.Evelyn Halford spent years as a paramedic — saving lives, running trauma codes, lifting bodies twice her size. But when Lyme disease hit, the same medical system she'd dedicated her career to told her it was all in her head.This is the story of what happens when you stop waiting for permission to heal — and start finding answers on your own.Episode Links & Resources:Clinical Consultation: https://simplecheckout.authorize.net/payment/CatalogPayment.aspx?LinkId=8c0d07f8-729c-4e9e-8322-193b6ba22744Website: https://www.ecorewellness.com/Instagram: https://www.instagram.com/ecorewellness/Connect with Tracy:Website: ⁠⁠⁠⁠⁠⁠https://tracyduhs.com/⁠⁠⁠⁠⁠⁠Hydration Shop: ⁠⁠⁠⁠⁠⁠https://sanctuarysd.com/⁠⁠⁠⁠⁠⁠Instagram: ⁠⁠⁠⁠⁠⁠@tracyduhs⁠⁠⁠⁠⁠⁠Flow FAM Community: ⁠⁠⁠⁠⁠⁠https://tracyduhs.com/join-flow-fam/

In this episode, I'm thrilled to welcome Hana Janebdar, co-founder and CEO of Juno Bio, all the way from London to discuss a topic I consider the new frontier in women's health: the vaginal microbiome. Hana brings incredible expertise with her background in biology and biochemical engineering from Imperial College London, and she's pioneering research that's closing the gender health gap. We dive into what the vaginal microbiome actually is, why it matters for your fertility journey, and how this community of bacteria and yeast living in your body can impact everything from IVF success rates to unexplained infertility. Read the full show notes on Dr. Aimee's website Throughout our conversation, Hana and I explore the fascinating connection between vaginal health and fertility outcomes, including the shocking statistic that women with disrupted vaginal microbiomes fail IVF 91% of the time. We discuss how bacterial imbalances can contribute to conditions like pelvic inflammatory disease and tubal factor infertility and why having a blocked tube doesn't automatically mean you had an STI. Hana shares how Juno Bio's at-home comprehensive vaginal microbiome test works, what you can learn from it, and the personalized treatment options available. This is essential information for anyone trying to conceive or optimize their reproductive health. In this episode, we cover: What the vaginal microbiome is and why 56% of your cells are actually microbial, not human How disrupted vaginal microbiomes impact IVF success rates and can cause a 91% failure rate The connection between vaginal bacteria and tubal factor infertility beyond STIs Why blocked fallopian tubes don't always mean you had a sexually transmitted infection How Juno Bio's at-home vaginal microbiome test works and what it reveals about your health Treatment options for vaginal microbiome imbalances, from antibiotics to targeted probiotics Why you should never douche and how your vagina is like a self-cleaning oven Resources:You can find out more about Juno Bio and Hana here: https://www.juno.bio/ Do you have questions about IVF? Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, February 9, 2026, at 4 pm PST, where Dr. Aimee will explain IVF and Egg Freezing, and there will be time to ask her your questions live on Zoom. Other ways to follow Dr. Aimee: Visit my YouTube channel for more fertility tipsSubscribe to the newsletter to get updatesJoin The Egg Whisperer SchoolRequest a Consultation with Dr. Aimee  Dr. Aimee Eyvazzadeh is one of America's most well‑known fertility doctors. Her success rate at baby‑making gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org. Keywords: vaginal microbiome, fertility, IVF success rates, bacterial vaginosis, tubal factor infertility, vaginal health, women's health, microbiome testing, at-home health test, Juno Bio, pelvic inflammatory disease, reproductive health, fertility testing, vaginal bacteria, probiotics for vaginal health, recurrent infections, fertility optimization, unexplained infertility, blocked fallopian tubes, vaginal dysbiosis, personalized women's health, fertility journey, reproductive microbiome

CHOP and the Richard D Wood Jr. Center for Fetal Diagnosis and Treatment is at the forefront of new medicine doing wonderful work to stem the 1 in 3 birth defects of babies born in the US. Mark interviews Dr. Scott Adzick in this episode.

Tonight on Hidden Killers Live, psychotherapist Shavaun Scott joins us for an extended examination of two cases that expose how systems fail families in catastrophic ways. From the psychology of family annihilation to the financial incentives keeping addiction treatment broken — this is essential expert analysis you won't find anywhere else.In the Paul Caneiro trial, prosecutors allege Paul murdered his brother Keith, sister-in-law Jennifer, and their two children at their Colts Neck mansion after Keith discovered Paul had been stealing from him. Eight-year-old Sophia was stabbed 17 times and allegedly still alive when the fire started. Shavaun breaks down what drives someone to annihilate everyone they love rather than face exposure, what extreme overkill reveals about psychological state, and how to read Paul's courtroom behavior — including his tears during testimony about the children.The Nick Reiner tragedy exposed America's $42 billion addiction treatment industry. The Reiner family had every resource available and Rob and Michele Reiner are still dead. Shavaun follows the money through relapse-profitable business models, insurance company control over clinical decisions, and the accountability vacuum that lets facilities fail without consequence. We identify who blocks reform and ask whether meaningful change is even possible. Join us live for unflinching expert analysis of family violence and institutional failure.#ShavaunScott #PaulCaneiro #NickReiner #RobReiner #FamilyAnnihilation #AddictionTreatment #ColtsNeckMurders #TreatmentIndustry #ExpertAnalysis #HiddenKillersLiveJoin Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspodInstagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/tonybpodListen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.

In today's episode, Neil Iyengar, MD, moderated an OncLive Insights discussion about adverse effect management when using breast cancer therapies targeting the PI3K, AKT, and mTOR pathways. Dr Iyengar is an associate professor in the Department of Hematology and Medical Oncology and co-director of Breast Medical Oncology in the Department of Hematology and Medical Oncology at Emory University School of Medicine; as well as director of Survivorship Services at the Winship Cancer Institute of Emory University in Atlanta, Georgia. He was joined by Heather Moore, CPP, PharmD, a clinical pharmacist practitioner at the Duke Cancer Center Breast Clinic in Durham, North Carolina; and Sarah Donahue, MPH, NP, a nurse practitioner at the University of California San Francisco Health.  In our exclusive discussion, the experts highlighted the importance of early and comprehensive testing (using both tissue and liquid biopsies) for genetic alterations to guide treatment decisions. They also noted strategies for managing diarrhea, including patient education on diet, proactive use of loperamide, and regular monitoring. They also explained that hyperglycemia management should hinge on prophylactic use of metformin or SGLT2 inhibitors, dietary restrictions, and frequent glucose monitoring. Their conversation on rash management included insights about prophylactic antihistamines, patient education on skin care, and involving dermatology for severe cases. Overall, the experts spotlighted the importance of multidisciplinary collaboration and proactive patient education when treating patients with breast cancer.

Reactive arthritis can come on suddenly—often after an infection—and leave you wondering why your joints (or tendons/back) are inflamed seemingly out of nowhere.In this video, Dr. Isabelle Amigues explains what reactive arthritis is, what commonly triggers it, how it's diagnosed, and what treatment and recovery can look like.We cover:--Common symptoms and patterns (joints, tendons, back pain—and sometimes eyes/skin)--Typical triggers (often after GI or GU infections)--How doctors evaluate it and what tests may be helpful--Treatment options and when to escalate care--Red flags to take seriously (especially eye symptoms)Question for you: Did your symptoms start after an illness or infection? Share your timeline in the comments.#ReactiveArthritis #Arthritis #Rheumatology #Inflammation #JointPain #AutoimmuneDisease #Spondyloarthritis #PostInfectiousArthritis #chronicillnesssupport 

Send us a textDo Heterogeneous Treatment Effects Exist?For the last 50 years, we've designed cars to be safe...For the 50th-percentile male.Well, that's actually not 100% correct.According to Stanford's report, we introduced "female" crash test dummies in the 1960s, but...They were just scaled-down versions of male dummies and...Represented the 5th percentile of females in terms of body size and mass (aka the smallest 5% of women in the general population).These dummies also did not take into account female-typical injury tolerance, biomechanics, spinal alignment, and more.But...Does it matter for actual safety?In the episode, we cover:- Do heterogeneous treatment effects (different effects in different contexts) exist?- If so, can we actually detect them?- Is it more ethical to look for heterogeneous treatment effects or rather look at global averages?Video version available on the Youtube: https://youtu.be/V801RQTBpp4Recorded on Nov 12, 2025 in Malaga, Spain.------------------------------------------------------------------------------------------------------About RichardProfessor Richard Hahn, PhD, is a professor of statistics at Arizona State University (ASU). He develops novel statistical methods for analyzing data arising from the social sciences, including psychology, economics, education, and business. His current focus revolves around causal inference using regression tree models, as well as foundational issues in Bayesian statistics.Connect with Richard:- Richard on LinkedIn: https://www.linkedin.com/in/richard-hahn-a1096050/About StephenStephen Senn, PhD, is a statistician and consultant who specializes in drug development clinical trials. He is a former Group Head at Ciba-Geigy and has taught at the University of Glasgow and University College London (UCL). He is the author of "Statistical Issues in Drug Development," "Crossover Trials in Clinical Research," and "Dicing with Death."Connect with Stephen:- Stephen on LinkedIn: Support the showCausal Bandits PodcastCausal AI || Causal Machine Learning || Causal Inference & DiscoveryWeb: https://causalbanditspodcast.comConnect on LinkedIn: https://www.linkedin.com/in/aleksandermolak/Join Causal Python Weekly: https://causalpython.io The Causal Book: https://amzn.to/3QhsRz4

New research shows that restoring glucose oxidation through the PDH enzyme — not burning more fat — is the key driver of meaningful and sustainable fat loss Obese animals lost fat while preserving muscle once PDH activity was restored, revealing a metabolic repair pathway that supports long-term weight control and higher energy Human muscle studies show that people with flexible fuel switching burn fat during fasting and glucose after meals, while metabolically rigid muscle stays stuck and promotes fat storage Fitness-focused interventions improve insulin sensitivity by strengthening mitochondrial function and restoring proper timing between fat use and glucose handling You can repair this system by lowering dietary fat, increasing healthy carbohydrates, supporting PDH with key nutrients, and using strategic movement to rebuild metabolic flexibility

BONJOUR! Head Noise today! So many questions coming through so we are ramping up these Head Noise episodes. Today we cover dating curses and how to break out of them, issues with friends who have given you the silent treatment, how to advance at work and stop being a soggy lemon and what to do when you take a step back for the sake of your mental health but it causes your mental health to continue to suffer because of the dreaded identity crisis. Lets get into it!! Learn more about your ad choices. Visit megaphone.fm/adchoices

After the deaths of Rob and Michele Reiner — allegedly at the hands of their son Nick — one question haunts every family dealing with addiction: why hasn't treatment gotten better? Fifty years of data showing 40-90% failure rates. An overdose crisis killing over 100,000 Americans annually. And yet the fundamental approach hasn't changed since insurance companies designed the 28-day model in the 1970s. On True Crime Today, we're following the money to find out why.Psychotherapist Shavaun Scott returns for Part 2 of our examination of America's broken treatment system. The industry is worth $42 billion. Every relapse is another admission, another billing cycle. Facilities get paid whether treatment works or not. There's no standardized outcome tracking, no required reporting of success rates, no transparency for families trying to make informed decisions. Insurance companies control treatment length through utilization review, overriding clinical judgment to prioritize cost containment.We examine who blocks reform — treatment industry lobbyists, insurance companies, pharmaceutical interests. The research showing what works exists and has for years: longer treatment, integrated mental health care, medication-assisted treatment. So what prevents evidence-based care from becoming standard? Is this regulatory capture, with the industry shaping rules to protect itself? Or is the system simply too entrenched to change? A critical examination of why profit keeps trumping outcomes.#NickReiner #RobReiner #MicheleReiner #AddictionProfits #TreatmentIndustry #ShavaunScott #RehabReform #InsuranceControl #OpioidCrisis #TrueCrimeTodayJoin Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspodInstagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/tonybpodListen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.

The deaths of Rob and Michele Reiner — allegedly at the hands of their son Nick — have sparked an uncomfortable national conversation. The Reiner family had every resource available. Money. Access. The ability to get the best treatment in the country. And here we are. So the question that keeps coming up: did the system fail them? Or is addiction simply this hard to treat?On True Crime Today, psychotherapist Shavaun Scott examines the reality behind America's addiction treatment industry. The relapse rates are staggering — 40-60% within 30 days, over 90% for opioids in the first year. The 28-day model that dominates treatment wasn't designed around brain science — it was designed around what insurance would cover back in the 1970s. Five decades later, we're still using it. And people are still dying.Shavaun breaks down what evidence-based treatment actually looks like versus what most people get. We examine the co-occurring disorder problem — addiction almost never exists alone, but most facilities aren't equipped to treat the underlying trauma and mental illness. The workforce crisis. The patients who learn to perform recovery without actually recovering. Is this an industry designed to fail? Or is it facing a disease that defeats every system built to treat it? Part one of a critical examination.#NickReiner #RobReiner #MicheleReiner #AddictionCrisis #RehabFailed #ShavaunScott #TreatmentIndustry #MentalHealth #SubstanceAbuse #TrueCrimeTodayJoin Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspodInstagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/tonybpodListen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.

The Reiner family had resources. Access. The ability to pay for the best treatment money could buy. And we're still here — with Rob and Michele Reiner dead and their son Nick charged with their murders. So here's what nobody wants to answer: if money and access couldn't fix this, what could? Is the addiction treatment system broken — or is this just what addiction does?Psychotherapist Shavaun Scott joins Hidden Killers to examine whether the treatment industry is failing by design or facing a disease that breaks everything it touches. The numbers are brutal: 40-60% relapse rates within 30 days of discharge. For opioids, over 90% in the first year. The 28-day model has been the standard since the 1970s — not based on brain science, but on what insurance companies decided to cover. Is that setting people up to fail before they walk in the door?We dig into the co-occurring disorder problem — addiction almost never travels alone, but most facilities aren't equipped to treat the trauma, depression, and mental illness underneath it. Shavaun explains what evidence-based treatment actually looks like, why it's not the norm, and the uncomfortable reality of patients who learn to perform recovery without doing the work. This is the first part of an unflinching examination of an industry that takes billions while delivering dismal results.#NickReiner #RobReiner #MicheleReiner #AddictionTreatmentFailed #RehabIndustry #ShavaunScott #SubstanceAbuse #MentalHealth #TreatmentCrisis #HiddenKillersJoin Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspodInstagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/tonybpodListen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.

Board-certified OB-GYN Dr. Mary Claire Haver breaks down what to know and look out for when it comes to menopause. Also, Alison Oliver stops by to catch up and share details about her role in the highly anticipated new film ‘Wuthering Heights.' Plus, a closer look at romance cyber scams — how to keep your identity safe and what to do if you or someone you know falls victim. And, Craig gets in the kitchen to whip up his delicious, supercharged chili recipe, perfect for a cozy winter night. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This podcast is brought to you by Outcomes Rocket, your exclusive healthcare marketing agency. Learn how to accelerate your growth by going to⁠ outcomesrocket.com Aligned incentives change behavior faster than technology alone ever could. In this episode, Dr. Farzad Mostashari, co-founder and CEO of Aledade, discusses how value-based care finally makes prevention profitable by rewarding primary care for keeping patients healthy rather than treating avoidable disease. He reflects on his path from public health and federal EHR leadership to building a nationwide platform that partners with independent practices to take total-cost-of-care contracts. Dr. Mostashari covers why fee-for-service warped EHRs into billing tools, how accountable care models reversed that logic, and why culture, long-term thinking, and technology at scale matter. He shares results from thousands of practices achieving higher blood-pressure control by focusing on stroke prevention, explains the economics of Medicare Shared Savings and expanding private contracts, and explores how AI can deliver just-in-time insights across hundreds of EHRs without forcing workflow change.  Tune in and learn how aligning incentives, primary care, and AI can deliver better outcomes at lower cost! Resources: Connect with and follow Dr. Farzad Mostashari on LinkedIn. Follow Aledade on LinkedIn and discover their website. Follow Aledade on LinkedIn and visit their website. Check out Aledade's Public Benefit Report and Medicare Shared Savings Program announcement.

Nick Reiner allegedly murdered his parents — director Rob Reiner and his wife Michele. The tragedy has forced a national conversation about something America has avoided for decades: the addiction treatment system doesn't work. Relapse rates between 40-60% within a month. Over 90% for opioids in the first year. A $42 billion industry that keeps billing whether treatment succeeds or not. Tonight on Hidden Killers Live, we're asking the hard question — is the system broken, or is this just what addiction looks like?Psychotherapist Shavaun Scott joins us to break down the clinical reality behind the headlines. The 28-day treatment model wasn't designed by doctors — it was designed by insurance companies in the 1970s. The brain doesn't heal from addiction in 28 days. So why is that still the standard? Shavaun examines what evidence-based treatment actually requires, why most facilities can't provide it, and whether we're expecting too much from a population that often doesn't want to recover.We're digging into the co-occurring disorder crisis — the trauma, depression, and mental illness that almost always accompanies addiction but rarely gets treated. The underpaid, undertrained workforce doing the frontline work. And the uncomfortable truth about patients who learn to game the system. Join us live as we examine whether the treatment industry is failing its patients or facing an impossible task.#NickReiner #RobReiner #AddictionTreatment #RehabFailure #ShavaunScott #MentalHealthCrisis #TreatmentIndustry #SubstanceAbuse #OpioidCrisis #HiddenKillersLiveJoin Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspodInstagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/tonybpodListen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.

Over 100,000 Americans die from overdoses every year. Relapse rates run 40-90%. The treatment model hasn't fundamentally changed since the 1970s. And yet the addiction treatment industry is worth $42 billion. Tonight on Hidden Killers Live, we're asking the question the industry doesn't want answered: is failure profitable? Is someone actively benefiting from keeping this system broken?Psychotherapist Shavaun Scott returns for Part 2 of our examination following the Nick Reiner tragedy. The Reiner family had every resource available and it still wasn't enough to save Rob and Michele Reiner. So we're following the money. Every relapse is another admission, another billing cycle. Insurance companies control treatment length through utilization review, overriding doctors. There's no standardized outcome tracking — families can't comparison shop for effectiveness because that data simply doesn't exist.We examine who fights reform when it's proposed. Treatment industry lobbyists. Insurance companies. Pharmaceutical interests. The research on what works is clear: longer treatment, integrated mental health care, medication-assisted treatment. So what's blocking evidence-based care from becoming standard practice? Is this regulatory capture — the industry shaping rules to protect itself? Or is the treatment industrial complex so entrenched that meaningful change is impossible? Join us live for an unflinching look at who profits from broken promises.#NickReiner #RobReiner #AddictionIndustry #TreatmentProfits #RehabReform #ShavaunScott #InsuranceScam #OpioidCrisis #HealthcareFraud #HiddenKillersLiveJoin Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspodInstagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/tonybpodListen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.

Psychogenic nonepileptic seizures (PNES) are common, often misunderstood, and increasingly encountered in pediatric emergency care. These events closely resemble epileptic seizures but arise from abnormal brain network functioning rather than epileptiform activity. In this episode of PEM Currents, we review the epidemiology, pathophysiology, and clinical features of PNES in children and adolescents, with a practical focus on Emergency Department recognition, diagnostic strategy, and management. Particular emphasis is placed on seizure semiology, avoiding iatrogenic harm, communicating the diagnosis compassionately, and understanding how early identification and referral to cognitive behavioral therapy can dramatically improve long-term outcomes. Learning Objectives Identify key epidemiologic trends, risk factors, and semiological features that help differentiate psychogenic nonepileptic seizures from epileptic seizures in pediatric patients presenting to the Emergency Department. Apply an evidence-based Emergency Department approach to the evaluation and initial management of suspected PNES, including strategies to avoid unnecessary escalation of care and medication exposure. Demonstrate effective, patient- and family-centered communication techniques for explaining the diagnosis of PNES and facilitating timely referral to appropriate outpatient therapy. References Sawchuk T, Buchhalter J, Senft B. Psychogenic Nonepileptic Seizures in Children-Prospective Validation of a Clinical Care Pathway & Risk Factors for Treatment Outcome. Epilepsy & Behavior. 2020;105:106971. (PMID: 32126506) Fredwall M, Terry D, Enciso L, et al. Outcomes of Children and Adolescents 1 Year After Being Seen in a Multidisciplinary Psychogenic Nonepileptic Seizures Clinic. Epilepsia. 2021;62(10):2528-2538. (PMID: 34339046) Sawchuk T, Buchhalter J. Psychogenic Nonepileptic Seizures in Children - Psychological Presentation, Treatment, and Short-Term Outcomes. Epilepsy & Behavior. 2015;52(Pt A):49-56. (PMID: 26409129) Labudda K, Frauenheim M, Miller I, et al. Outcome of CBT-based Multimodal Psychotherapy in Patients With Psychogenic Nonepileptic Seizures: A Prospective Naturalistic Study. Epilepsy & Behavior. 2020;106:107029. (PMID: 32213454) Transcript This transcript was generated using Descript automated transcription software and has been reviewed and edited for accuracy by the episode's author. Edits were limited to correcting names, titles, medical terminology, and transcription errors. The content reflects the original spoken audio and was not substantively altered. Welcome to PEM Currents: The Pediatric Emergency Medicine Podcast. As always, I'm your host, Brad Sobolewski, and today we are talking about psychogenic non-epileptic seizures, or PNES. Now, this is a diagnosis that often creates a lot of uncertainty in the Emergency Department. These episodes can be very scary for families and caregivers and schools. And if we mishandle the diagnosis, it can lead to unnecessary testing, medication exposure, ICU admissions, and long-term harm. This episode's gonna focus on how to recognize PNES in pediatric patients, how we make the diagnosis, what the evidence says about management and outcomes, and how what we do and what we say in the Emergency Department directly affects patients, families, and prognosis. Psychogenic non-epileptic seizures are paroxysmal events that resemble epileptic seizures but occur without epileptiform EEG activity. They're now best understood as a subtype of functional neurological symptom disorder, specifically functional or dissociative seizures. Historically, these events were commonly referred to as pseudo-seizures, and that term still comes up frequently in the ED, in documentation, and sometimes from families themselves. The problem is that pseudo implies false, fake, or voluntary, and that implication is incorrect and harmful. These episodes are real, involuntary, and distressing, even though they're not epileptic. Preferred terminology includes psychogenic non-epileptic seizures, or PNES, functional seizures, or dissociative seizures. And PNES is not a diagnosis of exclusion, and it does not require identification of psychological trauma or psychiatric disease. The diagnosis is based on positive clinical features, ideally supported by video-EEG, and management begins with clear, compassionate communication. The overall incidence of PNES shows a clear increase over time, particularly from the late 1990s through the mid-2010s. This probably reflects improved recognition and access to diagnostic services, though a true increase in occurrence can't be excluded. Comorbidity with epilepsy is really common and clinically important. Fourteen to forty-six percent of pediatric patients with PNES also have epilepsy, which frequently complicates diagnosis and contributes to diagnostic delay. Teenagers account for the highest proportion of patients with PNES, especially 15- to 19-year-olds. Surprisingly, kids under six are about one fourth of all cases, so it's not just teenagers. We often make the diagnosis of PNES in epilepsy monitoring units. So among children undergoing video-EEG, about 15 to 19 percent may ultimately be diagnosed with PNES. And paroxysmal non-epileptic events in tertiary epilepsy monitoring units account for about 15 percent of all monitored patients. Okay, but what is PNES? Well, it's best understood as a disorder of abnormal brain network functioning. It's not structural disease. The core mechanisms at play include altered attention and expectation, impaired integration of motor control and awareness, and dissociation during events. So the patients are not necessarily aware that this is happening. Psychological and psychosocial features are common but not required for diagnosis and may be less prevalent in pediatric populations as compared with adults. So PNES is a brain-based disorder. It's not conscious behavior, it's not malingering, and it's not under voluntary control. Children and adolescents with PNES have much higher rates of psychiatric comorbidities and psychosocial stressors compared to both healthy controls and children with epilepsy alone. Psychiatric disorders are present in about 40 percent of pediatric PNES patients, both before and after the diagnosis. Anxiety is seen in 58 percent, depression in 31 percent, and ADHD in 35 percent. Compared to kids with epilepsy, the risk of psychiatric disorders in PNES is nearly double. Compared to healthy controls, it is up to eight times higher. And there's a distinct somatopsychiatric profile that strongly predicts diagnosis of PNES. This includes multiple medical complaints, psychiatric symptoms, high anxiety sensitivity, and solitary emotional coping. This profile, if you've got all four of them, carries an odds ratio of 15 for PNES. Comorbid epilepsy occurs in 14 to 23 percent of pediatric PNES cases, and it's associated with intellectual disability and prolonged diagnostic delay. And finally, across all demographic strata, anxiety is the most consistent predictor of PNES. Making the diagnosis is really hard. It really depends on a careful history and detailed analysis of the events. There's no single feature that helps us make the diagnosis. So some of the features of the spells or events that have high specificity for PNES include long duration, so typically greater than three minutes, fluctuating or asynchronous limb movements, pelvic thrusting or side-to-side head movements, ictal eye closure, often with resisted eyelid opening, ictal crying or vocalization, recall of ictal events, and rare association with injury. Younger children often present with unresponsiveness. Adolescents more commonly demonstrate prominent motor symptoms. In pediatric cohorts, we most frequently see rhythmic motor activity in about 27 percent, and complex motor movements and dialeptic events in approximately 18 percent each. Features that argue against PNES include sustained cyanosis with hypoxia, true lateral tongue biting, stereotyped events that are identical each time, clear postictal confusion or lethargy, and obviously epileptic EEG changes during the events themselves. Now there are some additional historical and contextual clues that can help us make the diagnosis as well. If the events occur in the presence of others, if they occur during stressful situations, if there are psychosocial stressors or trauma history, a lack of response to antiepileptic drugs, or the absence of postictal confusion, this may suggest PNES. Lower socioeconomic status, Medicaid insurance, homelessness, and substance use are also associated with PNES risk. While some of these features increase suspicion, again, video-EEG remains the diagnostic gold standard. We do not have video-EEG in the ED. But during monitoring, typical events are ideally captured and epileptiform activity is not seen on the EEG recording. Video-EEG is not feasible for every single diagnosis. You can make a probable PNES diagnosis with a very accurate clinical history, a vivid description of the signs and appearance of the events, and reassuring interictal EEG findings. Normal labs and normal imaging do not make the diagnosis. Psychiatric comorbidities are not required. The diagnosis, again, rests on positive clinical features. If the patient can't be placed on video-EEG in a monitoring unit, and if they have an EEG in between events and it's normal, that can be supportive as well. So what if you have a patient with PNES in the Emergency Department? Step one, stabilize airway, breathing, circulation. Take care of the patient in front of you and keep them safe. Use seizure pads and precautions and keep them from falling off the bed or accidentally injuring themselves. A family member or another team member can help with this. Avoid reflexively escalating. If you are witnessing a PNES event in front of you, and if they're protecting their airway, oxygenating, and hemodynamically stable, avoid repeated benzodiazepines. Avoid intubating them unless clearly indicated, and avoid reflexively loading them with antiseizure medications such as levetiracetam or valproic acid. Take a focused history. You've gotta find out if they have a prior epilepsy diagnosis. Have they had EEGs before? What triggered today's event? Do they have a psychiatric history? Does the patient have school stressors or family conflict? And then is there any recent illness or injury? Only order labs and imaging when clinically indicated. EEG is not widely available in the Emergency Department. We definitely shouldn't say things like, “this isn't a real seizure,” or use outdated terms like pseudo-seizure. Don't say it's all psychological, and please do not imply that the patient is faking. If you see a patient and you think it's PNES, you're smart, you're probably right, but don't promise diagnostic certainty at first presentation. Remember, a sizable proportion of these patients actually do have epilepsy, and referring them to neurology and getting definitive testing can really help clarify the diagnosis. Communication errors, especially early on, worsen outcomes. One of the most difficult things is actually explaining what's going on to families and caregivers. So here's a suggestion. You could say something like: “What your child is experiencing looks like a seizure, but it's not caused by abnormal electrical activity in the brain. Instead, it's what we call a functional seizure, where the brain temporarily loses control of movement and awareness. These episodes are real and involuntary. The good news is that this condition is treatable, especially when we address it early.” The core treatment of PNES is CBT-based psychotherapy, or cognitive behavioral therapy. That's the standard of care. Typical treatment involves 12 to 14 sessions focused on identifying triggers, modifying maladaptive cognitions, and building coping strategies. Almost two thirds of patients achieve full remission with treatment. About a quarter achieve partial remission. Combined improvement rates reach up to 90 percent at 12 months. Additional issues that neurologists, psychologists, and psychiatrists often face include safe tapering of antiseizure medications when epilepsy has been excluded, treatment of comorbid anxiety or depression, coordinating care between neurology and mental health professionals, and providing education for schools on event management. Schools often witness these events and call prehospital professionals who want to keep patients safe. Benzodiazepines are sometimes given, exposing patients to additional risk. This requires health system-level and outpatient collaboration. Overall, early diagnosis and treatment of PNES is critical. Connection to counseling within one month of diagnosis is the strongest predictor of remission. PNES duration longer than 12 months before treatment significantly reduces the likelihood of remission. Video-EEG confirmation alone does not predict positive outcomes. Not every patient needs admission to a video-EEG unit. Quality of communication and speed of treatment, especially CBT-based therapy, matter the most. Overall, the prognosis for most patients with PNES is actually quite favorable. There are sustained reductions in events along with improvements in mental health comorbidities. Quality of life and psychosocial functioning improve, and patients use healthcare services less frequently. So here are some take-home points about psychogenic non-epileptic seizures, or PNES. Pseudo-seizure and similar terms are outdated and misleading. Do not use them. PNES are real, involuntary, brain-based events. Diagnosis relies on positive clinical features, what the events look like and when they happen, not normal lab tests or CT scans. Early recognition and diagnosis, and rapid referral to cognitive behavioral therapy, change patients' lives. If you suspect PNES, get neurology and mental health professionals involved as soon as possible. Alright, that's all I've got for this episode. I hope you found it educational. Having seen these events many times over the years, I recognize how scary they can be for families, schools, and our prehospital colleagues. It's up to us to think in advance about how we're going to talk to patients and families and develop strategies to help children who are suffering from PNES events. If you've got feedback about this episode, send it my way. Likewise, like, rate, and review, as my teenagers would say, and share this episode with a colleague if you think it would be beneficial. For PEM Currents: The Pediatric Emergency Medicine Podcast, this has been Brad Sobolewski. See you next time.

In this episode of Derms and Conditions, host James Q. Del Rosso, DO, is joined by Zoe Draelos, MD, for an in-depth discussion of 3 practical questions surrounding topical clascoterone, informed by studies Dr Draelos helped conduct. Together, they translate study findings into real-world considerations for using clascoterone as part of combination acne regimens. The conversation begins with the role of formulation and vehicle design, addressing a common concern in acne management: barrier disruption and application-site irritation. Unlike retinoids or benzoyl peroxide, clascoterone is an androgen receptor inhibitor formulated in a vehicle shown to sustain and slightly increase moisture content in the skin, supporting  barrier function while remaining compatible with other topical acne therapies. Data evaluating transepidermal water loss and corneometry demonstrate that the finished, marketed formulation sustains skin moisturization, reinforcing its barrier-friendly profile. The discussion then turns to real-world use, where clascoterone is frequently combined with other topical agents. An admixture stability study examined whether clascoterone degrades, or causes degradation of, commonly used acne treatments such as benzoyl peroxide, clindamycin, adapalene, and retinoids. Using chromatographic and mass spectrometric analysis, the study confirmed that clascoterone remains stable and compatible when layered with these agents. Finally, Dr Draelos reviews clinical data demonstrating progressive sebum reduction in patients with mild to moderate acne, measured using standardized sebumeter technology. Sebum levels decreased beginning around 12 weeks and continued to decline through 52 weeks, paralleling reductions in acne lesions, oily appearance, and visible pore size. Together, these findings clarify how clascoterone works at the target organ level and why its clinical benefits extend over time. Tune in to the episode to hear how these studies answer key mechanistic and practical questions about clascoterone, and how its barrier-friendly formulation, combination compatibility, and sustained sebum reduction may inform everyday acne management in clinical practice.

In today's episode, the discussion features Aditya Bardia, MD, MPH, FASCO. Dr Bardia is a professor in the Department of Medicine in the Division of Hematology/Oncology, the director of Translational Research Integration, and a member of Signal Transduction and Therapeutics at the UCLA Health Jonsson Comprehensive Cancer Center in Los Angeles, California.In the exclusive interview, Dr Bardia discussed the rationale and design of the phase 3 ELEGANT study (NCT06492616), which is evaluating elacestrant (Orserdu) compared with standard endocrine therapy in patients with estrogen receptor–positive, HER2-negative early breast cancer at high risk of disease recurrence.

Welcome to OncLive On Air®! OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today's episode, we welcomed John O. Mascarenhas, MD, a member of The Tisch Cancer Institute, a professor of medicine at the Icahn School of Medicine, and director of the Center of Excellence for Blood Cancers and Myeloid Disorders at Mount Sinai in New York, New York.In the exclusive interview, Dr Mascarenhas explored novel targeted therapeutic approaches being evaluated in patients with myeloproliferative neoplasms, including myelofibrosis and polycythemia vera. He outlined key reasons for investigating non–JAK inhibitor agents within this treatment paradigm; outlined data from a pair of phase 1 trials (NCT05936359; NCT06034002) evaluating the INCA033989 as monotherapy or in combination with ruxolitinib (Jakafi) in patients with CALR exon 9–mutated myelofibrosis; detailed another ongoing phase 1 study (NCT06313593) looking at INCB160058 in patients with MPNs; and explained how investigational targeted therapies could ultimately impact the MPN treatment paradigm.

It's 2026, and an estimated 4 million people will LOSE health insurance coverage in the coming months! Meanwhile, for those who do have insurance, premium costs and deductibles are skyrocketing! Living with hypothyroidism -- or hormonal issues like menopause, or hormonal weight gain -- is challenging enough! But what if you're trying to do it without health insurance? It can feel totally overwhelming. In this eye-opening episode of Paloma's podcast, we explore practical solutions, real-world strategies, and lesser-known pathways to manage your thyroid health affordably when traditional insurance isn't part of the picture. You'll hear compassionate discussion about why coverage gaps matter, how they impact everyday thyroid care, and ways to get the care you need without breaking the bank — or your spirit. Whether you're currently uninsured, between plans, or just curious about your options, this episode puts empowerment front and center. Here's what we break down in this episode: 

Two Democratic members of Congress visited the ICE family detention center in Dilley, Texas, where five-year-old Liam Ramos is being detained, along with many other children and families. Over the weekend, hundreds inside the facility protested their conditions and treatment in a display of defiance. Amna Nawaz spoke with immigration attorney Eric Lee, who was at the center that day. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

Dr. Mary Talley Bowden is an ear, nose, and throat physician and founder of BreatheMD, a direct-care ENT clinic that emphasizes transparent pricing and outpatient airway care. She completed her residency at Stanford University, and she is board-certified in otolaryngology and sleep medicine, focusing her practice on sinus, sleep, and allergy disorders. During the COVID-19 pandemic, Dr. Bowden became a nationally prominent physician for opposing vaccine mandates, advocating for early outpatient treatment, and engaging in high-profile legal and regulatory disputes with hospital systems and medical boards. She is also the author of Dangerous Misinformation: The Virus, the Treatments, and the Lies, a memoir about her COVID-19 work and clashes with medical institutions, set for release in May 2026. ------ Thank you to the sponsors that fuel our podcast and our team: AG1 https://drinkag1.com/tetra ------ LMNT Electrolytes https://drinklmnt.com/tetra Use code 'TETRA' ------ Squarespace https://squarespace.com/tetra Use code 'TETRA' ------ Sign up to receive Tetragrammaton Transmissions https://www.tetragrammaton.com/join-newsletter

The Nick Reiner case has forced America to confront an uncomfortable truth: our addiction treatment system isn't designed to help people get better. It's designed to keep them coming back.In this episode, we pull back the curtain on a $42 billion industry built on failure. Relapse rates hover between 40-60% after treatment. For opioids, some studies push that number past 90%. And the industry has known this for decades. Nothing has changed — because failure is the business model.We break down how the arbitrary 28-day treatment window became standard — not because of science, but because of insurance spreadsheets. How utilization review allows people with no medical training to override clinicians and deny coverage to patients in crisis. How families mortgage their homes and drain retirement accounts chasing hope, while facilities cash checks whether treatment works or not.The Reiner tragedy didn't happen in a vacuum. It happened inside a system with no accountability, no outcome tracking, and no consequences for failure. A system where the people doing the actual work — counselors making $38,000 a year — burn out while the industry generates billions.This isn't about blaming addicts. This is about exposing the machine that profits from their suffering and leaves families holding the bill.What would a system actually designed to help people look like? And why won't anyone with the power to change it do anything?#NickReiner #RobReiner #RehabIndustry #AddictionTreatment #TrueCrime Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspodInstagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/tonybpodListen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.

 Symptoms leading to diagnosis included progressively worsening headaches, tinnitus with pulsing in ears, dizziness, and immense head pressure during treadmill training that prompted an emergency eye exam revealing severe optic nerve bleeding.Surgery on November 1st, 2022 successfully removed 60 to 70% of the brain tumor, with the surgeon surprised Nathan didn't have a speech impediment given the tumor's extremely large size.Two weeks before diagnosis, Nathan heard a podcast about a man alleging to cure cancer with cannabis oil, and this person was providing the treatment free to cancer patients for seven years.Treatment protocol involved taking 10 pills daily containing 44 milligrams of cannabis each, combined initially with six cycles of chemotherapy and radiation, followed by six additional cycles of chemotherapy.Nathan's oncologist initially called the cannabis treatment a scam but later became encouraging about continuing the pills, stating Nathan was his best brain cancer patient at BC Cancer and that he never sees such results.Psychological impact included severe trauma for Nathan, his wife as caregiver, and 13-year-old son who witnessed Nathan crawling on floors due to extreme nausea and complications including a life-threatening blood clot.Cannabis provided multiple benefits including pain management, emotional regulation helping with depression, improved sleep for body recovery, and reduced inflammation which aided his athletic training recovery.Nathan was declared cancer free in 2023-2024 after continuous tumor shrinkage, with his oncologist stating he does not relate Nathan's success to the chemotherapy and radiation treatments.Multiple doctors have looked at Nathan's case and asked him to confirm his diagnosis, stating "you know you should be dead, right?" due to the rarity of his survival and recovery.Holistic healing approach included eliminating sugar, regular fasting for autophagy, sprouting broccoli for sulforaphane, taking vitamins C and D, and daily grounding by placing bare feet on earth for 30 minutes.A false positive scare occurred in November 2025 when an MRI showed what appeared to be recurrence, but December scan confirmed it was an artifact and Nathan remained cancer free.Nathan now coaches other cancer patients and has seen success with three people who experienced pseudoprogression (inflammation mistaken for tumor growth) that later showed actual shrinkage on subsequent scans.His dog was diagnosed with aggressive malignant melanoma in November 2025 with high mitotic count and given weeks to months to live, but is now being treated with the same cannabis oil formula designed for pets.Cancer experience completely transformed Nathan's perspective from being depressed and unmotivated before diagnosis to becoming extremely positive and passionate about helping others explore cannabis treatment options. Visit our website: CannabisHealthRadio.comFind high-quality cannabis and CBD + get free consultations at MyFitLife.net/cannabishealthDiscover products and get expert advice from Swan ApothecaryFollow us on Facebook.Follow us on Instagram.Find us on Rumble.Keep your privacy! Buy NixT420 Odor Remover Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Got a question?

After more than 20 years in practice, I've noticed there are certain treatment areas that consistently create change across a wide range of complaints. The key isn't the technique but understanding why these areas matter and when to address them.In this episode of the Unreal Results podcast, I share five treatment regions I find myself coming back to again and again across elite athletes, Navy SEAL candidates, and complex cases. These are high-payoff regions that consistently influence the body as a whole when addressed with intention.In this episode, you'll learn:How nerve pathways and fascial relationships explain why these areas matter far beyond local painWhy sequencing matters more than the tool you're usingHow to apply these concepts without overcomplicating your sessionsThis episode isn't about adding more techniques, it's about sharpening your ability to recognize the areas that matter most in each session.Resources & Links Mentioned In This Episode:Episode 9: Left Side Sciatica or Right Side Shoulder Pain?Episode 26: Sartorius B.I.G.Episode 28: The Power Of The Trigeminal NerveEpisode 70: How The Trigeminal Nerve Could Supercharge Your PracticeEpisode 73: The Sartorius: It's More Powerful Than You ThinkEpisode 86: Decoding The Nervous System For Health Pros Episode 142: The Most Overlooked Skill In Clinical PracticeTreatment Video: Superior Gluteal Nerve GlideTreatment Video: Manual Technique For Superior Gluteal NerveTreatment Video: Neural Manipulation Technique For Superior Gluteal NerveOnline Course: Go-To Treatments For The Viscera & Nervous SystemLearn the LTAP® In-Person in one of my upcoming coursesConsidering the viscera as a source of musculoskeletal pain and dysfunction is a great way to ensure a more true whole body approach to care, however it can be a bit overwhelming on where to start, which is exactly why I created the Visceral Referral Cheat Sheet. This FREE download will help you to learn the most common visceral referral patterns affecting the musculoskeletal system. Download it at www.unrealresultspod.com=================================================Watch the podcast on YouTube and subscribe!Join the MovementREV email list to stay up to date on the Unreal Results Podcast and MovementREV education. Be social and follow me:Instagram | Facebook | Twitter | YouTube

In this episode, Catrina Simbe-Geriak shares the story behind the creation of Tyler's Grace Foundation, a mission born from a critical meeting where the conversation shifted to home care and the difficult reality of dying.Our discussion explores the profound moments experienced by patients, caregivers, and families as they navigate end of life visions, serious illness, and the compassionate role of palliative care at the end of life. Catrina reflects on how faith, presence, and service can bring dignity and peace during life's most vulnerable chapters.This conversation offers insight into how loss can be transformed into purpose and how compassionate care can create meaning, comfort, and connection even at the end of life.Please learn more about Tyler's Grace Foundation or connect with Catrina:Website: https://tylersgracefoundation.org/Catrina's LinkedIn: https://www.linkedin.com/in/catrina-simbe-geriak-4355131/0:00 Preview: Hospice, the Ocean, and the Birth of a Mission0:39 Introduction: Meet Catrina Simbe-Geriak2:12 Early Life, Grit, and a People-First Calling3:47 Tyler's Diagnosis: A Childhood Cancer Journey Begins6:38 Two Surgeries, Treatment, and a Family Under Pressure7:40 A Second Diagnosis: Fighting Cancer on Two Fronts15:16 “Best Day Ever”: Tyler's Mindset and Life Lessons18:00 The Hardest Meeting: Hospice, Palliative Care, and Letting Go20:07 The Beach House: Making the Final Months Count22:56 Grief, Faith, and Healing After Compound Loss27:40 Tyler's Grace Foundation: Creating Protected Memories31:24 The Future: Lake Almanor Home, Never Saying No, and Legacy______________________________________________________________If this episode inspires you to be part of the movement, and you believe, like me, that entrepreneurs are the answer to our future, message me so we can join forces to support building truly great companies in our region. -Subscribe to my channel here: https://www.youtube.com/channel/UCom_​... -  Mark Haney is a serial entrepreneur that has experience growing companies worth hundreds of millions of dollars. He is currently the CEO and founder of HaneyBiz -  Instagram: http://instagram.com/themarkhaney​ Facebook: www.facebook.com/themarkhaney LinkedIn: https://www.linkedin.com/in/markehaney​ Website: http://haneybiz.com​ Audio Boom: https://audioboom.com/channels/5005273​  Twitter: http://twitter.com/themarkhaney-This video includes personal knowledge, experiences, and opinions about Angel Investing by seasoned angel investors.  This content is for informational purposes only and should not be construed as legal, tax, investment, or financial advice.  Nothing in this video constitutes a solicitation, recommendation, or endorsement.#thebackyardadvantage #themarkhaneyshow #entrepreneur #PowerOfWith #SacramentoEntrepreneur #Sacramento#SacramentoSmallBusiness #SmallBusiness #GrowthFactory #Investor#Podcast

It's new year, new me season! And if you're wondering what's new and exciting in cosmetic procedures, we've got you covered.We're joined by Chief Medical Officer of Sono Bello® to explore what's shaping the future of body contouring and cosmetic surgery. He discusses the rise in male cosmetic procedures, the impact of GLP-1 weight loss medications, and why more patients are leaning towards natural-looking results. Plus, Dr. Chung shares how advancements in technology are helping shorten recovery time and expand treatment options—yes, lasers included. This episode is brought to you in partnership with Sono Bello®​   This podcast is not a substitute for professional medical advice, diagnosis, or treatment. This podcast is for informational purposes only. Treatment and results may vary based upon the circumstances, situation, and medical judgment after appropriate discussion. The content contained on this podcast does not create a doctor-patient relationship and all surgery carries inherent risks and the outcomes depend on individual circumstances. Always seek the advice of your surgeon or other qualified health provider with any questions you may have regarding medical care. Never disregard professional medical advice or delay seeking advice because of something on this podcast.​   Care Experts is a weekly podcast by CareCredit where we sit down with doctors and experts who give information, tips and insight into healthcare treatments and procedures. Check in every Wednesday for new episodes at carecredit.com/careexperts or follow on your favorite podcast app. CareCredit is a health, wellness and personal care credit card that has helped millions of people with promotional financing options and is accepted at hundreds of thousands of provider and retail locations nationwide. Learn more at carecredit.com.

From Discovery to Delivery: Charting Progress in Gynecologic Oncology, hosted by Ursula A. Matulonis, MD, brings expert insights into the most recent breakthroughs, evolving standards, and emerging therapies across gynecologic cancers. Dr Matulonis is chief of the Division of Gynecologic Oncology and the Brock-Wilcon Family Chair at the Dana-Farber Cancer Institute, as well as a professor of medicine at Harvard Medical School, both in Boston, Massachusetts.In this episode, Dr Matulonis sat down with guest Rebecca Porter, MD, PhD. Dr Porter is a physician at Dana-Farber Cancer Institute and an assistant professor of medicine at Harvard Medical School.Drs Matulonis and Porter discussed the evolving role of immunotherapy in gynecologic cancer management, focusing on recent clinical breakthroughs and future directions. They noted that although high-grade serous ovarian cancer has historically been refractory to immunotherapy, the phase 3 KEYNOTE-B96 trial (NCT05116189) demonstrated an efficacy benefit with the addition of pembrolizumab to weekly paclitaxel for patients with platinum-resistant disease. In particular, improvements in overall survival were noted in the PD-L1–positive patient population. Dr Porter attributed this success to the metronomic weekly dosing of paclitaxel, which may increase neoantigen levels and favorably alter the tumor microenvironment (TME).Moreover, the experts highlighted how immunotherapy has already become the standard of care for patients with mismatch repair–deficient advanced or recurrent endometrial cancer. However, they explained that for the mismatch repair–proficient population, this benefit is less clear and appears most significant in patients with measurable disease or specific molecular subtypes. They added that although circulating tumor DNA (ctDNA) assay results correlate with treatment outcomes, ctDNA is currently not an actionable biomarker for determining treatment duration or selection.Lastly, Drs Matulonis and Porter reported that the field of gynecologic oncology is shifting toward combination therapies and novel platforms beyond standard checkpoint inhibitors. Treatment advances include bispecific and trispecific antibodies that engage multiple cell types or signals; as well as adoptive cellular therapies, such as CAR T-cell and CAR natural killer–cell therapies. Ultimately, the experts concluded that the goal of managing challenging-to-treat diseases like ovarian cancer is to use combinatorial approaches—incorporating vaccines, anti-angiogenic therapies, and chemotherapy—to overcome the immunosuppressive nature of the TME.

Advanced skin treatments often underperform for a reason rarely addressed: regeneration cannot occur in a chronically stressed or under-resourced system. Elevated cortisol, inflammation, and metabolic imbalance weaken collagen signaling and tissue repair before any device, injectable, or modality has a chance to work.In this episode of the Biohacking Beauty Podcast, we sit down with Joe Radich from R3 Health to unpack why physiological preparation determines treatment outcomes. We explore how internal factors like stress, hormones, micronutrients, and metabolic health shape skin regeneration, and why modalities like peptides, hyperbaric oxygen, and exosomes only work as well as the system they're introduced into.Joe Radich is an NCCPA board-certified Physician Assistant specializing in regenerative medicine and the founder of R3 Health. He trains physicians and mid-level practitioners in stem cells, PRP, exosomes, and biohacking-based clinical protocols, with expertise spanning orthopedic, aesthetic, hair restoration, and regenerative applications.What's Discussed:(06:42) Why chronic stress and cortisol are silent drivers of visible skin aging(10:18) Preparing the body before skin treatments and why physiology determines outcomes(14:07) Why microneedling success depends on internal biology, not just technique(18:55) The most common lab patterns behind poor skin regeneration and chronic inflammation(24:31) Hormonal imbalance vs hormone deficiency and how both affect skin aging(33:41) GHK-Cu and peptides as signaling tools for connective tissue regeneration(38:09) Hyperbaric oxygen as a force multiplier for skin repair, recovery, and longevity(44:06) Exosomes and regenerative biologics and why sourcing and quality determine resultsFind more from Young Goose:VAMPIRE EXOSOMES → Professional Exosome Serum for Regeneration and Post-Treatment Recovery → Vampire ExosomesUse code PODCAST10 to get 10% off your first purchase, and if you're a returning customer use the code PODCAST5 to get 5% off at www.younggoose.com Instagram: @young_goose_skincareWinter Skincare Protocol: https://www.younggoose.com/pages/winter-protocol Find more from Joe Radich (R3 Health):Website: https://josephradich.com, https://r3health.coInstagram: @joeradich_

Two Democratic members of Congress visited the ICE family detention center in Dilley, Texas, where five-year-old Liam Ramos is being detained, along with many other children and families. Over the weekend, hundreds inside the facility protested their conditions and treatment in a display of defiance. Amna Nawaz spoke with immigration attorney Eric Lee, who was at the center that day. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

There are potential new treatments emerging in 2026 for the treatment of atopic dermatitis and psoriasis. How do these treatments work and where will they fit into the treatment landscape? Jennifer Soung, MD gives an overview. Plus, Andrea Nguyen, DMSc, MPAS, PA-C provides an update on CSU treatment and Sandri Johnson, MSN, FNP-BC, DCNP and Alexa Hetzel, DMSc, PA-C celebrate the popularity of the dermatology specialty.Like what you're hearing? Want to learn more about the Dermatology Education Foundation? Explore assets and resources on our website.

  Fertility Docs Uncensored is hosted by Dr. Carrie Bedient from the Fertility Center of Las Vegas, Dr. Susan Hudson from Texas Fertility Center, and Dr. Abby Eblen from Nashville Fertility Center. What is ovarian hyperstimulation syndrome (OHSS)? OHSS is a condition that can occur after ovarian stimulation, most often during IVF cycles, when the ovaries respond excessively to fertility medications. Who is at highest risk for OHSS? Patients at increased risk include women with a high egg count, younger patients, and patients with PCOS (polycystic ovary syndrome). Does pregnancy increase the risk of OHSS? Yes; a fresh embryo transfer can increase the risk because the pregnancy hormone (hCG) may worsen or prolong OHSS symptoms. How has the risk of OHSS decreased in modern IVF treatment? The use of GnRH agonist (Lupron) trigger shots has dramatically reduced the risk by quickly lowering estrogen levels and preventing severe symptoms. How is OHSS treated? Treatment focuses on symptom management; medications such as cabergoline (Dostinex) and letrozole may be used to lower estrogen levels and shorten symptom duration. When should patients call their doctor about OHSS symptoms? Patients should call immediately if they experience low urine output, an inability to drink fluids, severe abdominal pain, shortness of breath, or pain or swelling in the arms or legs. Why is it important to call your doctor if you are concerned? OHSS can be serious, and early evaluation and treatment are critical. Patients should always contact their doctor if they are worried about symptoms. This podcast was sponsored by U.S. Fertility. 

➡️ Get the full episode breakdown at Biology of Trauma® Podcast - Episode Family Member Struggling with Addiction? Why Treatment Fails If you've watched a family member struggle with addiction, you know how helpless it can feel. Treatment programs that don't work. Policies that seem disconnected from reality. Debates about legalization versus criminalization that never address what actually helps someone recover. Dr. Kevin Sabet has spent decades advising three presidential administrations on drug policy—watching decriminalization debates, marijuana legalization, and the opioid crisis unfold. He started asking a different question: What if we looked at what actually works? His book One Nation Under the Influence examines why current addiction policies are failing—and what Iceland, Portugal, and Hawaii figured out that we're missing. In This Episode You'll Learn: [01:00] Why marijuana is the most misunderstood drug in America [04:00] How today's marijuana is genetically bred to be far more potent [08:00] The critical difference between decriminalization, legalization, and commercialization [12:00] Why the promises of marijuana legalization haven't materialized [17:00] How addiction responds to incentives unlike any other brain condition [20:00] What "harm reduction" actually means—and why there's so much confusion [24:00] Why some addiction physicians recommend marijuana for opioid recovery—and what the research shows [30:00] What Iceland's prevention model actually did differently [33:00] How Portugal's system works—and why it's not legalization [35:00] Hawaii's HOPE program: why 2 days in jail changed behavior when years of probation didn't

On this week’s episode, we’re continuing our Guidelines Series exploring the 2022 ESC/ERS Guidelines for the diagnosis and treatment of Pulmonary Hypertension. If you missed our first episode in the series, give it a listen to hear about the most recent recommendations regarding Pulmonary Hypertension definitions, screening, and diagnostics. Today, we’re talking about the next steps after diagnosis. Specifically, we’ll be discussing risk stratification, establishing treatment goals, and metrics for re-evaluation. We’ll additionally introduce the mainstays of pharmacologic therapy for Pulmonary Hypertension. Meet Our Co-Hosts Rupali Sood  grew up in Las Vegas, Nevada and made her way over to Baltimore for medical school at Johns Hopkins. She then completed her internal medicine residency training at Massachusetts General Hospital before returning back to Johns Hopkins, where she is currently a pulmonary and critical care medicine fellow. Rupali’s interests include interstitial lung disease, particularly as related to oncologic drugs, and bedside medical education. Tom Di Vitantonio  is originally from New Jersey and attended medical school at Rutgers, New Jersey Medical School in Newark. He then completed his internal medicine residency at Weill Cornell, where he also served as a chief resident. He currently is a pulmonary and critical care medicine fellow at Johns Hopkins, and he’s passionate about caring for critically ill patients, how we approach the management of pulmonary embolism, and also about medical education of trainees to help them be more confident and patient centered. Key Learning Points 1) Episode Roadmap How to set treatment goals, assess symptom burden, and risk-stratify patients with suspected/confirmed pulmonary arterial hypertension (PAH). What tools to use to re-evaluate patients on treatment Intro to major PAH medication classes and how they map to pathways. 2) Case-based diagnostic reasoning Patient: 37-year-old woman with exertional dyspnea, mild edema, abnormal echo, telangiectasias + epistaxis → raises suspicion for HHT (hereditary hemorrhagic telangiectasia) and/or early connective tissue disease. Key reasoning move: start broad (Groups 2–5) and narrow using history/exam/testing. In a young patient without obvious left heart or lung disease, think more about Group 1 PAH (idiopathic/heritable/associated). HHT teaching point: HHT can cause PH in more than one way: More common: high-output PH from AVMs (often hepatic/pulmonary) Rare (1–2% mentioned): true PAH phenotype (vascular remodeling; associated with ALK1 in some patients), behaving like Group 1 PAH. 3) Functional class assessment WHO Functional Class: Class I: no symptoms with ordinary activity, only with exertion Class II: symptoms with ordinary activity Class III: symptoms with less-than-ordinary activity (can't do usual chores/shopping without dyspnea) Class IV: symptoms at rest Practical bedside tip they give: Ask if the patient can walk at their own pace or keep up with a similar-age peer/partner. If not, think Class II (or worse). 4) Risk stratification at diagnosis: why, how, and which tools Big principle: treatment choices are driven by risk, and the goal is to move patients to low-risk quickly. ESC/ERS approach at diagnosis (as described): Use a 3-strata model predicting 1-year mortality: Low: 20% ESC/ERS risk assessment variables (10 domains discussed): Clinical progression, signs of right heart failure, syncope WHO FC Biomarkers (NT-proBNP) Exercise capacity (6MWD) Hemodynamics Imaging (echo; sometimes cardiac MRI) CPET (peak VO₂; VE/VCO₂ slope) They note: even if you don't have everything, the calculator can still be useful with ≥3 variables. REVEAL 2.0: Builds on similar core variables but adds further patient context (demographics, renal function, BP, DLCO, etc.) Case result: both tools put her in intermediate risk (ESC/ERS ~1.6; REVEAL 2.0 score 8), underscoring that mild symptoms can still equal meaningful mortality risk. 5) Treatment goals and follow-up philosophy What they explicitly prioritize: Help patients feel better, live longer, and stay out of the hospital Use risk tools to communicate prognosis and to track improvement Reassess frequently (they mention ~every 3 months early on) until low risk is achieved “Time-to-low-risk” is an important treatment goal Also emphasized: The diagnosis is psychologically heavy; patients need clear counseling, reassurance about the plan, and connection to support groups. 6) Medication classes for the treatment of PAH Nitric oxide–cGMP pathway PDE5 inhibitors: sildenafil, tadalafil Soluble guanylate cyclase stimulator: riociguat Important safety point: don't combine PDE5 inhibitors with riociguat (risk of significant hypotension/hemodynamic effects) Endothelin receptor antagonists (ERAs) “-sentan” drugs: bosentan (less used due to side effects/interactions), ambrisentan, macitentan Teratogenicity emphasized Hepatotoxicity that requires LFT monitoring Can cause fluid retention and peripheral edema Prostacyclin pathway Prostacyclin analogs/agonists: Epoprostenol (potent; short half-life; IV administration) Treprostinil (IV/SubQ/oral/inhaled options) Selexipag (oral prostacyclin receptor agonist) 7) Sotatercept (post-guidelines) They note sotatercept wasn't in 2022 ESC/ERS but is now “a game changer” in practice: Mechanism: ligand trap affecting TGF-β signaling / remodeling biology Positioned as potentially more disease-modifying than pure vasodilators Still evolving: where to place it earlier vs later in regimens is an active question in the field 8) How risk category maps to initial treatment intensity General approach they outline: High risk at diagnosis: parenteral prostacyclin (IV/SubQ) strongly favored, often aggressive early Intermediate risk: at least dual oral therapy (typically PDE5i + ERA); escalate if not achieving low risk Low risk: at least one oral agent; many still use dual oral depending on etiology/trajectory For the case: intermediate-risk → start dual oral therapy (they mention tadalafil + ambrisentan as a typical choice), reassess in ~3 months; add a third agent (e.g., selexipag/prostacyclin pathway) if not low risk.  References and Further Reading Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, Ferreira DS, Ghofrani HA, Giannakoulas G, Kiely DG, Mayer E, Meszaros G, Nagavci B, Olsson KM, Pepke-Zaba J, Quint JK, Rådegran G, Simonneau G, Sitbon O, Tonia T, Toshner M, Vachiery JL, Vonk Noordegraaf A, Delcroix M, Rosenkranz S; ESC/ERS Scientific Document Group. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022 Oct 11;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237. Erratum in: Eur Heart J. 2023 Apr 17;44(15):1312. doi: 10.1093/eurheartj/ehad005. PMID: 36017548. Condon DF, Nickel NP, Anderson R, Mirza S, de Jesus Perez VA. The 6th World Symposium on Pulmonary Hypertension: what’s old is new. F1000Res. 2019 Jun 19;8:F1000 Faculty Rev-888. doi: 10.12688/f1000research.18811.1. PMID: 31249672; PMCID: PMC6584967. Maron BA. Revised Definition of Pulmonary Hypertension and Approach to Management: A Clinical Primer. J Am Heart Assoc. 2023 Apr 18;12(8):e029024. doi: 10.1161/JAHA.122.029024. Epub 2023 Apr 7. PMID: 37026538; PMCID: PMC10227272. Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Grünig E, Kopeć G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M; STELLAR Trial Investigators. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023 Apr 20;388(16):1478-1490. doi: 10.1056/NEJMoa2213558. Epub 2023 Mar 6. PMID: 36877098. Ruopp NF, Cockrill BA. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. 2022 Apr 12;327(14):1379-1391. doi: 10.1001/jama.2022.4402. Erratum in: JAMA. 2022 Sep 6;328(9):892. doi: 10.1001/jama.2022.13696. PMID: 35412560.

These everyday symptoms could be warning signs you have SIBO. In this episode, I've compiled research on four conditions that could actually be underlying signals that you have small intestinal bacterial overgrowth. This may surprise you!    ✅ Need guidance on your healing journey? Learn more about our virtual clinic: https://drruscio.com/virtual-clinic/

Today, we dive into one of the most critical topics in chiropractic care: the real-world effectiveness of strategies for implementing guideline-concordant care for low back pain. We'll explore recent research that asks a simple but powerful question—do strategies designed to promote best practices in low back pain management actually change provider behavior?Research: Effectiveness of strategies for implementing guideline-concordant care in low back pain: a systematic review and meta-analysis of randomised controlled trialsSpecial Offers for Listeners: Learn more about Diabetes Reversal Group and become a licenseeSave $500 and Get a Free Cart- Learn more at Shockwave Center of America Today!Leander Tables- Save $1,000 on the Series 950 Table using the code EBC2025 — their most advanced flexion-distraction tableNovoPulse OA Recovery Program- learn more herePatient Pilot by The Smart Chiropractor is the fastest, easiest to generate weekly patient reactivations on autopilot…without spending any money on advertising. Click here to schedule a call with our team.Our members use research to GROW their practice. Are you interested in increasing your referrals? Discover the best chiropractic marketing you aren't currently using right here!